Z-(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol | 200956-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Z-(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol
• 英文别名: tert-butyl (2S,3R)-3-hydroxy-3-[(Z)-3-hydroxyprop-1-enyl]-2-phenylpiperidine-1-carboxylate
• CAS: 200956-75-8
• 化学式: C₁₉H₂₇NO₄
• 分子量: 333.428
• InChiKey: KDNJOJIWLSKVGR-FDQLTWNHSA-N

物化性质

• 沸点：
  478.8±45.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Z-(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol 在 lithium chloride palladium diacetate 、 四丁基氯化铵 、 potassium formate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Stereocontrolled Syntheses of Epimeric 3-Aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 Receptor Antagonist Precursors

  摘要：

  [GRAPHICS]Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a was achieved through hydrogenation of an arylated dihydrofuran, whereas the corresponding stereogenic center in 1b was installed using a stereo- and regioselective alkene hydroarylation.

  DOI：

  10.1021/ol006944a
• 作为产物：
  描述：

  cis-(3S)-hydroxy-(2S)-phenylpiperidine 在 Lindlar's catalyst 草酰氯 、 四丁基氟化铵 、 氢气 、 sodium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， -70.0~20.0 ℃ 、101.33 kPa 条件下， 反应 9.0h， 生成 Z-(2S,3R)-1-tert-butoxycarbonyl-3-(3-hydroxyprop-1-en-1-yl)-2-phenylpiperidin-3-ol
  参考文献：
  名称：

  Stereocontrolled Syntheses of Epimeric 3-Aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 Receptor Antagonist Precursors

  摘要：

  [GRAPHICS]Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a was achieved through hydrogenation of an arylated dihydrofuran, whereas the corresponding stereogenic center in 1b was installed using a stereo- and regioselective alkene hydroarylation.

  DOI：

  10.1021/ol006944a

文献信息

• Use of NK-1 receptor antagonists for treating stress disorders
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06087348A1

  公开（公告）日：2000-07-11

  The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.

  本发明提供了口服活性长效、穿透中枢神经系统的NK-1受体拮抗剂的使用，用于制备适用于口服治疗或预防压力障碍的药物，无需同时使用其他抗压药物，以及使用该NK-1受体拮抗剂进行治疗的方法和包含它的药物组合物。
• Use of NK-1 receptor antagonists for treating major depressive disorders
  申请人：Merck Sharp & Dohme Limited

  公开号：US06613765B1

  公开（公告）日：2003-09-02

  The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

  本发明提供了治疗重度抑郁症的方法，包括口服给药口服活性、长效、穿透中枢神经系统的NK-1受体拮抗剂，以及包含这种NK-1受体拮抗剂的药物组合物。
• Use of NK-1 receptor antagonists for treating bipolar disorders
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05977104A1

  公开（公告）日：1999-11-02

  The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

  本发明提供了治疗或预防双相情感障碍的方法，而无需同时使用其他抗抑郁或抗焦虑药物，该方法包括口服给药口服活性、长效、穿透中枢神经系统的NK-1受体拮抗剂，以及包含该NK-1受体拮抗剂的药物组合物。
• Use of NK-1 receptor antagonists for treating cognitive disorders
  申请人：Merck Sharp & Dohme Limited

  公开号：US06271230B1

  公开（公告）日：2001-08-07

  The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

  本发明提供了治疗或预防认知障碍的方法，其中包括口服具有口服活性、长效、能穿透中枢神经系统的NK-1受体拮抗剂，并且还提供了包含这种NK-1受体拮抗剂的制药组合物。
• Spiro-azacyclic derivatives, their preparation and their use as
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06046195A1

  公开（公告）日：2000-04-04

  The present invention relates to certain spiro-azacyclic derivatives which are tachykinin antagonists and are useful, for example, in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.

  本发明涉及某些螺环氮杂环衍生物，其是速激肽拮抗剂，并且可用于治疗或预防疼痛、炎症、偏头痛、恶心和带状疱疹后神经痛等症状。